Zileuton (bibliography)
Out of date but seems like a good place to start:
Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157:1187-94.
Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5- lipoxygenase inhibitors. Am J Respir Crit Care Med. 1998;157:S233-7.
Gomez FP, Iglesia R, Roca J, et al. The effects of 5-lipoxygenase inhibition by zileuton on platelet- activating-factor-induced pulmonary abnormalities in mild asthma. Am J Respir Crit Care Med. 1998;157:1559-64.
Schwartz HJ, Petty T, Dube LM, et al. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. Arch Intern Med. 1998;158:141-8.
Tan RA. The role of antileukotrienes in asthma management. Curr Opin Pulm Med. 1998;4:25-30.
Dekhuijzen PN, Bootsma GP, Wielders PL, et al. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. Eur Respir J. 1997;10:2749-53.
DuBuske LM, Grossman J, Dube LM, et al. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am J Manag Care. 1997;3:633-40.
Lau R. Drug interactions with zileuton [letter]. Lancet. 1997;349:1479-80.
Munoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med. 1997;155:1398-403.
O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997;111:27S-34S.
Sorkness CA. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy. 1997;17:50S-54S.
Zileuton for asthma. Med Lett Drugs Ther. 1997;39:18-9.
Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy. 1996;26:868-79.
Hendeles L, Marshik PL. Zileuton: a new therapy for asthma or just the first of a new class of drugs [comment]. Ann Pharmacother. 1996;30:873-5.
Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996;275:931-6.
Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 1996;97:646-54.
Larsen JS, Jackson SK. Antileukotriene therapy for asthma. Am J Health Syst Pharm. 1996;53:2821-30.
Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996;98:859-71.
McGill KA, Busse WW. Zileuton. Lancet. 1996;348:519-24.
Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5- lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931-5.
Wenzel SE, Kamada AK. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother. 1996;30:858-64.
Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 1995;8:1203-13.
Drazen JM, Israel E. Treatment of chronic stable asthma with drugs active on the 5- lipoxygenase pathway. Int Arch Allergy Immunol. 1995;107:319-20.
Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 1995;152:1203-7.
Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995;29 Suppl 2:77-83.
Malo PE, Bell RL, Shaughnessy TK, et al. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm Pharmacol. 1994;7:73-9.
Bell RL, Lanni C, Malo PE, et al. Preclinical and clinical activity of zileuton and A-78773. Ann N Y Acad Sci. 1993;696:205-15.
Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to- moderate asthma. Ann Intern Med. 1993;119:1059-66.
Abraham WM, Ahmed A, Cortes A, et al. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. Eur J Pharmacol. 1992;217:119-26.
Bell RL, Young PR, Albert D, et al. The discovery and development of zileuton: an orally active 5- lipoxygenase inhibitor. Int J Immunopharmacol. 1992;14:505-10.
Busse WW, Gaddy JN. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis. 1991;143:S103-7.
Carter GW, Young PR, Albert DH, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991;256:929-37.
Rubin P, Dube L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions Suppl. 1991;35:103-16.
Compiled 7/30/99. Based on MedLine Update through June, 1999. A Scanlan Bibliography |
